雅培Abbott Laboratories (ABT) 2017年年度報告「NYSE」.pdf

《雅培Abbott Laboratories (ABT) 2017年年度報告「NYSE」.pdf》由會員分享，可在線閱讀，更多相關《雅培Abbott Laboratories (ABT) 2017年年度報告「NYSE」.pdf（82頁珍藏版）》請在三個皮匠報告上搜索。

1、ABBOTT 2017 ANNUAL REPORT2017 ANNUAL REPORTABBOTT.COM1009764ab_cvr.indd13/2/1810:36 AMPlease carefully do a final review of art and text to insure correctness and accuracy.Digital color representation may not be accurate,use actual Pantone color specifications.After clients final approval is receive

2、d,SandyAlexanderis not responsible for errors or legal compliance.Any changes made after receipt of clients final approval of art and text is clients responsibility.Die lines and call-outs exist on individual layers to be removed prior to processing.Customer Name:Date:Operator:CSR:Job Number:File Na

3、me:Page Size:File URL:200 Entin Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|02-Mar-1802-Mar-181009764ab_cvr_1_T1009764ab_cvr_1_T LasserKaren LasserAbbott Labs_1552Abbott Labs_1552CMYKzfold17.1875 X 11.000017.1875 X 11.0000TABLE OF CONTENTS1Letter to Shareholders5This is Abbott10Diabet

4、es Care12Cardiac Rhythm Management14Heart Failure16Structural Heart and Vascular Care18Neuromodulation20Established Pharmaceuticals22Nutrition26Diagnostics31Abbott FutureAbbott is a global healthcare company whose diversebusinesses help people live fuller lives through betterhealth.We keep hearts he

5、althy,nourish bodies at everystage of life,help people feel and move better,and provideinformation,medicines,and breakthrough technologiesto manage peoples health.With growing businessesin both developed and developing economies offeringmarket-leading products that align with long-termdemographic an

6、d technological trends,we are creatinglong-term shareholder value by delivering consistentgrowth,strong cash flow,and steadily increasing returns.Since 2015,Gabrielle hasrelied on the revolutionarytechnology in AbbottsFreeStyle Libre system tomonitor her glucose levels.on the cover:GABRIELLE WEMPEFr

7、eeStyle Libre userThe Netherlands1009764ab_cvr.indd23/2/1810:36 AMPlease carefully do a final review of art and text to insure correctness and accuracy.Digital color representation may not be accurate,use actual Pantone color specifications.After clients final approval is received,SandyAlexanderis n

8、ot responsible for errors or legal compliance.Any changes made after receipt of clients final approval of art and text is clients responsibility.Die lines and call-outs exist on individual layers to be removed prior to processing.Customer Name:Date:Operator:CSR:Job Number:File Name:Page Size:File UR

9、L:200 Entin Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|02-Mar-1802-Mar-181009764ab_cvr_1_T1009764ab_cvr_1_T LasserKaren LasserAbbott Labs_1552Abbott Labs_1552CMYK29252925spzfold17.1875 X 11.000017.1875 X 11.0000DEAR FELLOW SHAREHOLDER:Abbott is here to create value.We do so by helpin

10、g the people who use our products achieve better health.And we do soby helping our shareholders achieve financial growth.2017 was an outstanding year for our company in both respects.1009764ab_txt.indd13/2/1811:39 AMMILES D.WHITEChairman of the Board and Chief Executive OfficerPlease carefully do a

11、final review of art and text to insure correctness and accuracy.Digital color representation may not be accurate,use actual Pantone color specifications.After clients final approval is received,SandyAlexanderis not responsible for errors or legal compliance.Any changes made after receipt of clients

12、final approval of art and text is clients responsibility.Die lines and call-outs exist on individual layers to be removed prior to processing.Customer Name:Date:Operator:CSR:Job Number:File Name:Page Size:File URL:200 Entin Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|02-Mar-181009764a

13、b_txt_T LasserAbbott Labs_1552CMYK29258.5000 X 11.0000LETTER TO OUR SHAREHOLDERSACCELERATING GROWTHESTABLISHEDPHARMACEUTICALS9.5%GROWTH 2DIABETES CARE20%GROWTHdriven byFreeStyleLibreNEUROMODULATION40%GROWTH1led by newlylaunchedproductsbalanced acrossemergingmarkets2A B B O T T 2 0 1 7 A N N U A L R

14、E P O R TFOCUS ON THE FUTUREThe way we consistently createand deliver that value is by keepingour focus squarely on the future.This year marks our companys130th anniversary.But our viewis that were only as old as our lastyear that Abbott is a perpetuallynew company with a long legacyof success that

15、informs where wego next and how we get there.Thats a powerful combination:the experience of a company thatssucceeded for generations,andthe ambition and energy of a newcompany with fresh opportunities.We work very deliberately to ensurethat Abbott remains always relevantand current to the people we

16、serveand to the changes taking place inour environment.To that end,wecontinually shape the company,strategically choosing the businessesin which we compete,the areas ofresearch in which we invest,and thegeographies in which we build,toachieve the optimal configurationfor success.2017 was a watershed

17、 year in theshaping of our business for its nextgreat era.The most conspicuoussteps in this process were two majoracquisitions that will be powerfuldrivers of our future.The first of these was St.JudeMedical,the addition of which madeAbbott a leading medical-deviceinnovator.Second was Alere Inc.,ale

18、ader in rapid-testing technologies.St.Jude and Alere both enhanceour strength and presence in keybusinesses.Weve long been a majorglobal player in Diagnostics;Alerestrengthens us in one of the fewareas in which we werent already aleader.St.Jude,on the other hand,makes us a premier company acrossthe

19、spectrum of cardiac care,wherewed previously had leadershiponly in certain focused areas.Italso brings us into a very promisingnew field:Neuromodulation totreat chronic pain and movementdisorders.Were now the marketleader in non-opioid pain-relieftechnology,an area of high interestand immense potent

20、ial.Equally important over time ishow we strengthen the companyorganically,through our investmentin research and development.2017was a year of great success andproductivity for Abbott innovation,with an extraordinary numberof major product launches andapprovals across our businesses andaround the wo

21、rld.We have never hada more robust new-product pipelineof life-changing technologies.Whilethis is detailed throughout thisreport,Ill call out two examples ofinternal Abbott innovation that speakto our broad aims and capabilities.1009764ab_txt.indd23/2/18 8:19 PMPlease carefully do a final review of

22、art and text to insure correctness and accuracy.Digital color representation may not be accurate,use actual Pantone color specifications.After clients final approval is received,SandyAlexanderis not responsible for errors or legal compliance.Any changes made after receipt of clients final approval o

23、f art and text is clients responsibility.Die lines and call-outs exist on individual layers to be removed prior to processing.Customer Name:Date:Operator:CSR:Job Number:File Name:Page Size:File URL:200 Entin Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|02-Mar-181009764ab_txt_p_2_3_13_1

24、5_T LasserAbbott Labs_1552CMYK29258.5000 X 11.0000LETTER TO OUR SHAREHOLDERSINCREASING OUR IMPACTCARDIOVASCULAR12NEWPRODUCTSLaunchedacrosscategoriesDIAGNOSTICS6NEWSYSTEMSin ourAlinity FamilyNUTRITIONin WorldwideAdult Nutrition#1A B B O T T 2 0 1 7 A N N U A L R E P O R T3First is our FreeStyle Libre

25、 glucose-monitoring system.The FreeStyleLibre system is a leap-froggingtechnology,changing the way peoplehave managed their diabetes fordecades.And it clearly demonstratesour strategic approach in action:we entered this field throughacquisition,creating Abbott DiabetesCare in 2004;then developed it

26、strategically and technologically into the market leader it is today.The years other standout exampleof Abbott innovation is our Alinityfamily of diagnostic systems.This isa project of unprecedented scope andambition in its market a reinventionof the way the diagnostic lab worksthrough a simultaneou

27、s reimaginingof its component systems.Whatsparticularly striking about this effortis that it comes in a legacy businessin which Abbott has long been anestablished leader but,nonetheless,isexecuting a game-changing strategythrough organic R&D.SHAPING SUCCESSWe continually build Abbottto achieve a car

28、efully definedprofile that weve found optimalfor achieving consistently strongperformance.We craft thatcompetitive profile to ensureour company is structured onthese purposefully cultivatedcore strengths:BalanceThe diversity of Abbotts businessportfolio not only expands ouropportunities to more area

29、s ofhealthcare,its the key to our abilityto deliver superior results.Bymanaging a careful balance betweendiverse elements in our business mix,our customer base,and the marketswe serve,we have more ways to winwithout being overly dependent onany single part of our business.Global PresenceAbbott has s

30、trong commercial,manufacturing,and R&Dinfrastructure throughout theworlds largest and fastest-growingmarkets.And our marketing effortshave now brought Abbotts corporateidentity to more than three billionpeople worldwide.AlignmentAbbott goes where significanthealth needs align with scientificopportun

31、ity in order to make thegreatest impact for patients and,consequently,shareholders.Ourability to understand the needs of ourcustomers allows us to move withthe evolution of our markets.LeadershipOur intent is to be the leadingcompany in the markets in which wecompete.And were fulfilling thatobjectiv

32、e,with#1 or#2 positions invirtually every market we serve.1009764ab_txt.indd33/2/18 8:19 PMPlease carefully do a final review of art and text to insure correctness and accuracy.Digital color representation may not be accurate,use actual Pantone color specifications.After clients final approval is re

33、ceived,SandyAlexanderis not responsible for errors or legal compliance.Any changes made after receipt of clients final approval of art and text is clients responsibility.Die lines and call-outs exist on individual layers to be removed prior to processing.Customer Name:Date:Operator:CSR:Job Number:Fi

34、le Name:Page Size:File URL:200 Entin Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|02-Mar-181009764ab_txt_p_2_3_13_15_T LasserAbbott Labs_1552CMYK29258.5000 X 11.0000LETTER TO OUR SHAREHOLDERSMiles D.WhiteChairman of the Boardand Chief Executive OfficerMarch 2,2018CREATING VALUEThe resu

35、lts of the steps weve takenbear out the strategies behind them.The amount of value Abbott hascreated near-and long-term is extraordinary.Our company performed very wellin 2017,and the result was a stellaryear for Abbott shares.Our stockgrew almost 50 percent in 2017 its best performance in 20 years

36、hitting more than 20 all-time highsalong the way.Combined with dividends paid,this resulted in total shareholderreturn of 52 percent,the best inour fundamental peer group.And,for the long term,weve paid risingdividends for the past 46 consecutiveyears,keeping us a member of theS&P Dividend Aristocra

37、ts Indexsince its inception.Were able to create great valuefinancially because we first do soin the lives of the people who useour products and for others whoselives we touch.In 2017,our efforts inglobal citizenship led us to be namedto the Dow Jones SustainabilityIndexes for the 13th consecutiveyea

38、r,the fifth in a row as the leaderin our industry.As a result of thisstrong performance across ouroperations,Fortune magazinerecently named us the Most AdmiredCompany in our industry,also for thefifth consecutive year.2017 was,then,a landmarkyear of building and putting thepieces in place for our ne

39、xt leapforward.In the years ahead we willcapitalize on those investments andadvancements.As this report makesclear,we are superbly positionedto do so.Thanks to our continual shapingof the company,Abbott is in arange of businesses,geographies,and technologies that will allowus to keep growing,evolvin

40、g,andsucceeding.With our eyes always onthe way ahead,our company is newagain,for the 130th time,and readierthan ever to create the ultimatevalue in human lives improved andpotential realized.A TRADITION OF GROWTHConsistent long-term performance and outstanding shareholder returns52%1-year Total Retu

41、rnto Shareholdersas of December 29,2017of consecutive quarterlydividends paidAbbott has been an S&P 500Dividend Aristocrat since the listwas first compiledyears90+4A B B O T T 2 0 1 7 A N N U A L R E P O R T1009764ab_txt.indd43/5/1811:34 AMPlease carefully do a final review of art and text to insure

42、 correctness and accuracy.Digital color representation may not be accurate,use actual Pantone color specifications.After clients final approval is received,SandyAlexanderis not responsible for errors or legal compliance.Any changes made after receipt of clients final approval of art and text is clie

43、nts responsibility.Die lines and call-outs exist on individual layers to be removed prior to processing.Customer Name:Date:Operator:CSR:Job Number:File Name:Page Size:File URL:200 Entin Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|05-Mar-181009764ab_txt_rev_T LasserAbbott Labs_1552CMYK

44、29258.5000 X 11.0000THIS ISABBOTTExecuting our strategies,accelerating our growth,expandingourimpact.1009764ab_txt.indd53/5/1811:37 AMPlease carefully do a final review of art and text to insure correctness and accuracy.Digital color representation may not be accurate,use actual Pantone color specif

45、ications.After clients final approval is received,SandyAlexanderis not responsible for errors or legal compliance.Any changes made after receipt of clients final approval of art and text is clients responsibility.Die lines and call-outs exist on individual layers to be removed prior to processing.Cu

46、stomer Name:Date:Operator:CSR:Job Number:File Name:Page Size:File URL:200 Entin Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|05-Mar-181009764ab_txt_p5_T LasserAbbott Labs_1552Y3025PANTONE 3025_sp8.5000 X 11.0000BUILDINGON OURCORESTRENGTHS.BALANCEin our business mix,ourcustomer base,and

47、 themarkets we serveALIGNMENTwith the most significantneeds and trends inhealthcare6A B B O T T 2 0 1 7 A N N U A L R E P O R T1009764ab_txt.indd63/2/1811:39 AMPlease carefully do a final review of art and text to insure correctness and accuracy.Digital color representation may not be accurate,use a

48、ctual Pantone color specifications.After clients final approval is received,SandyAlexanderis not responsible for errors or legal compliance.Any changes made after receipt of clients final approval of art and text is clients responsibility.Die lines and call-outs exist on individual layers to be remo

49、ved prior to processing.Customer Name:Date:Operator:CSR:Job Number:File Name:Page Size:File URL:200 Entin Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|02-Mar-181009764ab_txt_T LasserAbbott Labs_1552CMYK292530258.5000 X 11.00007LEADERSHIPwith#1 or#2 positions in virtuallyevery market we

50、 servePRESENCEin the worlds largest andfastest-growingmarkets71009764ab_txt.indd73/2/1811:40 AMPlease carefully do a final review of art and text to insure correctness and accuracy.Digital color representation may not be accurate,use actual Pantone color specifications.After clients final approval i

51、s received,SandyAlexanderis not responsible for errors or legal compliance.Any changes made after receipt of clients final approval of art and text is clients responsibility.Die lines and call-outs exist on individual layers to be removed prior to processing.Customer Name:Date:Operator:CSR:Job Numbe

52、r:File Name:Page Size:File URL:200 Entin Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|02-Mar-181009764ab_txt_T LasserAbbott Labs_1552CMYK8.5000 X 11.0000LIFE-CHANGINGTECHNOLOGY8A B B O T T 2 0 1 7 A N N U A L R E P O R T1009764ab_txt.indd83/2/1811:40 AMPlease carefully do a final revie

53、w of art and text to insure correctness and accuracy.Digital color representation may not be accurate,use actual Pantone color specifications.After clients final approval is received,SandyAlexanderis not responsible for errors or legal compliance.Any changes made after receipt of clients final appro

54、val of art and text is clients responsibility.Die lines and call-outs exist on individual layers to be removed prior to processing.Customer Name:Date:Operator:CSR:Job Number:File Name:Page Size:File URL:200 Entin Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|02-Mar-181009764ab_txt_T Las

55、serAbbott Labs_1552CMYK30258.5000 X 11.0000Abbott creates life-changing technologies that helppeople live healthier,fuller lives.Our relentlesspursuit of invention is delivering an unprecedentednumber of advances that will extend our impactand sustain our growth for years to come.A B B O T T 2 0 1 7

56、 A N N U A L R E P O R T91009764ab_txt.indd93/2/1811:40 AMPlease carefully do a final review of art and text to insure correctness and accuracy.Digital color representation may not be accurate,use actual Pantone color specifications.After clients final approval is received,SandyAlexanderis not respo

57、nsible for errors or legal compliance.Any changes made after receipt of clients final approval of art and text is clients responsibility.Die lines and call-outs exist on individual layers to be removed prior to processing.Customer Name:Date:Operator:CSR:Job Number:File Name:Page Size:File URL:200 En

58、tin Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|02-Mar-181009764ab_txt_T LasserAbbott Labs_1552CMYK30258.5000 X 11.0000HELPING PEOPLE WITH DIABETESlive fuller,healthier lives.FREESTYLE LIBRE1 0A B B O T T 2 0 1 7 A N N U A L R E P O R T1009764ab_txt.indd103/2/1811:40 AMPlease carefull

59、y do a final review of art and text to insure correctness and accuracy.Digital color representation may not be accurate,use actual Pantone color specifications.After clients final approval is received,SandyAlexanderis not responsible for errors or legal compliance.Any changes made after receipt of c

60、lients final approval of art and text is clients responsibility.Die lines and call-outs exist on individual layers to be removed prior to processing.Customer Name:Date:Operator:CSR:Job Number:File Name:Page Size:File URL:200 Entin Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|02-Mar-181

61、009764ab_txt_T LasserAbbott Labs_1552CMYK30258.5000 X 11.000048%INCREASEprojected in the numberofpeople livingwith diabetesby 2045 4FREESTYLELIBRELINKAbbotts mobile applicationbrings FreeStyle Libremonitoring functionality tousers smartphones.425millionpeople worldwidehave someform of diabetes.3PARA

62、DIGM-SHIFTINGTECHNOLOGYAbbott is revolutionizing the waypeople monitor their glucose withour FreeStyle Libre system.Thisbreakthrough technology measuresglucose levels through a small sensorworn on the back of the upperarm,eliminating the need for routinefinger sticks.5More than half a million people

63、worldwide rely on the FreeStyle Libresystem to provide real-time glucoseresults,a graph depicting the latesteight hours of glucose history,and atrend arrow showing the directiontheir glucose is heading.The systemstouch-screen reader retains up to 90days of data,allowing people to tracktheir glucose

64、levels over time.NEXT-GENERATION SOLUTIONSIn 2017,Abbott began collaboratingwith Bigfoot Biomedical to developdiabetes-management systems,integrating our FreeStyle Libretechnology with Bigfoots insulin-delivery solutions.Through thiscollaboration,we aim to provide moreactionable information for peop

65、le whorely on daily insulin injectionsto manage their diabetes.ABBOTT IS COMMITTED TOHELPING PEOPLE ACROSSTHE WORLD MANAGETHEIR DIABETES MORECOMFORTABLY ANDEFFECTIVELY.Gabrielle appreciatesthe freedom afforded her byAbbotts FreeStyle Libreglucose-monitoring systemGABRIELLEWEMPERotterdam,The Netherla

66、ndsA B B O T T 2 0 1 7 A N N U A L R E P O R T1 11009764ab_txt.indd113/2/1811:40 AMPlease carefully do a final review of art and text to insure correctness and accuracy.Digital color representation may not be accurate,use actual Pantone color specifications.After clients final approval is received,S

67、andyAlexanderis not responsible for errors or legal compliance.Any changes made after receipt of clients final approval of art and text is clients responsibility.Die lines and call-outs exist on individual layers to be removed prior to processing.Customer Name:Date:Operator:CSR:Job Number:File Name:

68、Page Size:File URL:200 Entin Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|02-Mar-181009764ab_txt_T LasserAbbott Labs_1552CMYK292530258.5000 X 11.0000ENSITE PRECISIONCARDIACMAPPING SYSTEMAbbotts cardiac mappingsystem offers next-generationtechnology that provides ahigh level of automati

69、on,flexibility,and precision tohelp doctors more effectivelydiagnose a wide range ofarrhythmias.Hearts that beat too fast,too slow,or out ofsync pump blood less effectively,which canresult in damage to the brain,heart,andother organs.Abbotts portfolio of cardiac-rhythm-management devices includespac

70、emakers that restore normal rhythm,implantable cardiac defibrillators(ICD)that help slow abnormally fast-beatinghearts,and cardiac-resynchronizationdevices that help the heart pump in a morecoordinated way.Doctors can also analyzeand treat abnormal heart rhythms usingour advanced mapping and visuali

71、zationsystems,along with our diagnostic andablation catheters.EXPANDING OUR PORTFOLIOIn 2017,we expanded our market-leading cardiac-rhythm-managementportfolio with the U.S.Food and DrugAdministration(FDA)approvals of severalimportant advances:our FlexAbilityAblation Catheter,designed to improveversa

72、tility and precision during proceduresto treat atrial flutter,a type of irregularheartbeat;Confirm Rx,the worldsfirst and only smartphone-compatibleinsertable cardiac monitor,designed tohelp physicians remotely identify cardiacarrhythmias;and our full suite of cardiac-rhythm-management products,incl

73、udingour Assurity MRI pacemaker and EllipseICD,that are specifically designed to allowfull-body MRI scans.ABBOTT IS CONTINUALLYFOCUSED ON INCREASINGTHE BREADTH ANDDEPTH OF ITS CARDIAC-RHYTHM-MANAGEMENTPORTFOLIO.12A B B O T T 2 0 1 7 A N N U A L R E P O R T1009764ab_txt.indd123/2/1811:40 AMPlease car

74、efully do a final review of art and text to insure correctness and accuracy.Digital color representation may not be accurate,use actual Pantone color specifications.After clients final approval is received,SandyAlexanderis not responsible for errors or legal compliance.Any changes made after receipt

75、 of clients final approval of art and text is clients responsibility.Die lines and call-outs exist on individual layers to be removed prior to processing.Customer Name:Date:Operator:CSR:Job Number:File Name:Page Size:File URL:200 Entin Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|02-Ma

76、r-181009764ab_txt_T LasserAbbott Labs_1552CMYK29258.5000 X 11.0000KEEPING HEARTS HEALTHYand beating at a steady pace.With a family history of heartdisease,and evidence that shedsuffered an undiagnosed attackherself,Rachael appreciates thepeace of mind offered by herAbbott Fortify VR implantablecardi

77、overter defibrillator.RACHAELJARNAGINChicago,Illinois,USAEstimated number of people in theUnited States who experience someform of cardiac arrhythmia.614millionASSURITYMRIPACEMAKERA B B O T T 2 0 1 7 A N N U A L R E P O R T1 31009764ab_txt.indd133/2/18 8:19 PMPlease carefully do a final review of ar

78、t and text to insure correctness and accuracy.Digital color representation may not be accurate,use actual Pantone color specifications.After clients final approval is received,SandyAlexanderis not responsible for errors or legal compliance.Any changes made after receipt of clients final approval of

79、art and text is clients responsibility.Die lines and call-outs exist on individual layers to be removed prior to processing.Customer Name:Date:Operator:CSR:Job Number:File Name:Page Size:File URL:200 Entin Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|02-Mar-181009764ab_txt_p_2_3_13_15_

80、T LasserAbbott Labs_1552CMYK30258.5000 X 11.0000BREAKTHROUGH SOLUTIONSto help heart-failure patients live fuller lives.HEARTMATE 3LEFT-VENTRICULARASSISTDEVICE1 4A B B O T T 2 0 1 7 A N N U A L R E P O R T1009764ab_txt.indd143/2/18 3:42 PMPlease carefully do a final review of art and text to insure c

81、orrectness and accuracy.Digital color representation may not be accurate,use actual Pantone color specifications.After clients final approval is received,SandyAlexanderis not responsible for errors or legal compliance.Any changes made after receipt of clients final approval of art and text is client

82、s responsibility.Die lines and call-outs exist on individual layers to be removed prior to processing.Customer Name:Date:Operator:CSR:Job Number:File Name:Page Size:File URL:200 Entin Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|02-Mar-181009764ab_txt_p_14_15_27_T LasserAbbott Labs_155

83、2CMYK29258.5000 X 11.000046%The HeartMate 3 LVAD,for advanced heart-failure patients,usesfull magnetic levitationas it pumps,reducingtrauma to blood passingthrough the system.26 millionProjected risein heart failure inthe U.S.by 2030 8people worldwidesuffer fromheart failure 7A B B O T T 2 0 1 7 A N

84、 N U A L R E P O R T1 5Reggie relies on AbbottsHeartMate 3 Left-VentricularAssist Device to help himenjoy a fuller life withhis wife,Michelle,while heawaits his transplant.Abbotts Heart Failure portfoliocomprises devices and systems totreat and manage heart failure formany different kinds of patient

85、s.Ourcomprehensive offering includesimplantable cardiac-resynchronizationdevices;specially designed pacemakersand defibrillators;our CardioMEMSpulmonary-artery pressure monitor,which lets doctors detect worseningheart failure before a patient feelssymptoms;a remote monitoring systemthat communicates

86、 with doctorswithout the need for an in-office visit;and left ventricular assist devices(LVAD),implantable pumps thatsupport patients living with advancedheart failure.Our newest device in this categoryis the HeartMate 3 LVAD,whichis the first implantable device ofits kind to use our proprietary Ful

87、lMagLev technology,designed toreduce trauma to the blood passingthrough the pump,while optimizingblood flow.Improved blood flow canhelp reduce the risk of blood-clotformation,while continuing to deliverthe best patient therapy possible.ABBOTT OFFERS ACOMPREHENSIVE PORTFOLIOOF DEVICES AND SYSTEMSDESI

88、GNED TO ADDRESS EVERYTYPE OF HEART FAILURE.REGGIEWILLIAMSRaleigh,North Carolina,USA1009764ab_txt.indd153/2/18 8:19 PMPlease carefully do a final review of art and text to insure correctness and accuracy.Digital color representation may not be accurate,use actual Pantone color specifications.After cl

89、ients final approval is received,SandyAlexanderis not responsible for errors or legal compliance.Any changes made after receipt of clients final approval of art and text is clients responsibility.Die lines and call-outs exist on individual layers to be removed prior to processing.Customer Name:Date:

90、Operator:CSR:Job Number:File Name:Page Size:File URL:200 Entin Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|02-Mar-181009764ab_txt_p_2_3_13_15_T LasserAbbott Labs_1552CMYK29258.5000 X 11.0000AMPLATZERSEPTALOCCLUDER71,000children in the U.S.and European Unionare born with structuralhear

91、t defects each year.9LESS-INVASIVE THERAPIESWith mitral-valve-repair devices,as well astranscatheter aortic-valve replacement andsurgical valve products,Abbott now hasthe broadest offering of technologies thattreat structural-heart diseases,such as non-functioning heart valves and life-threateningho

92、les in the heart.Our MitraClip,a first-of-its-kind mitral-valve-repair device,has provided aminimally invasive treatment option formore than 50,000 people worldwide.Andour AMPLATZER septal occluder is the firstapproved medical device indicated to reducethe risk of recurrent ischemic stroke inpatient

93、s with a small opening between theupper chambers of the heart.ADVANCING THE STATE OF THE ARTToday,our vascular business offers market-leading stents,catheters,guidewires,and vessel-closure devices,along withdiagnostic and imaging devices that allowcardiologists to better visualize damagedarteries.By

94、 combining imaging capabilitywith stenting,we can offer the rightcombination of information and tools to helpdoctors make better decisions in treatingcoronary artery disease.In 2017,Abbott received European approvalfor XIENCE Sierra,a next-generation stentdesigned to make it easier to access difficu

95、lt-to-reach lesions.ABBOTT IS IMPROVINGTREATMENT OPTIONSIN BOTH STRUCTURAL HEARTAND VASCULAR DISEASE.1 6A B B O T T 2 0 1 7 A N N U A L R E P O R T1009764ab_txt.indd163/2/1811:40 AMPlease carefully do a final review of art and text to insure correctness and accuracy.Digital color representation may

96、not be accurate,use actual Pantone color specifications.After clients final approval is received,SandyAlexanderis not responsible for errors or legal compliance.Any changes made after receipt of clients final approval of art and text is clients responsibility.Die lines and call-outs exist on individ

97、ual layers to be removed prior to processing.Customer Name:Date:Operator:CSR:Job Number:File Name:Page Size:File URL:200 Entin Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|02-Mar-181009764ab_txt_T LasserAbbott Labs_1552CMYK29258.5000 X 11.0000REPAIRING DAMAGED HEARTSand restoring healt

98、hy blood flow.XIENCE SIERRACORONARYSTENTAfter doctors used AbbottsMitraClip device to repair hisleaky mitral valve,Dick regainedthe energy he needed to trulyenjoy his retirement.DICKCOTHRANAvon Park,Florida,USAMITRACLIPMITRAL-VALVEREPAIR DEVICEA B B O T T 2 0 1 7 A N N U A L R E P O R T171009764ab_t

99、xt.indd173/2/1811:40 AMPlease carefully do a final review of art and text to insure correctness and accuracy.Digital color representation may not be accurate,use actual Pantone color specifications.After clients final approval is received,SandyAlexanderis not responsible for errors or legal complian

100、ce.Any changes made after receipt of clients final approval of art and text is clients responsibility.Die lines and call-outs exist on individual layers to be removed prior to processing.Customer Name:Date:Operator:CSR:Job Number:File Name:Page Size:File URL:200 Entin Road|Clifton,NewJersey 07014|p

101、973.470.8100|f 973.470.9269|02-Mar-181009764ab_txt_T LasserAbbott Labs_1552CMYK30258.5000 X 11.0000CUTTING-EDGE SCIENCEto treat chronic pain and movement disorders.INFINITYDeep BrainStimulationSystemPROCLAIMNEUROSTIMULATIONSYSTEM1 8A B B O T T 2 0 1 7 A N N U A L R E P O R T1009764ab_txt.indd183/2/1

102、811:40 AMPlease carefully do a final review of art and text to insure correctness and accuracy.Digital color representation may not be accurate,use actual Pantone color specifications.After clients final approval is received,SandyAlexanderis not responsible for errors or legal compliance.Any changes

103、 made after receipt of clients final approval of art and text is clients responsibility.Die lines and call-outs exist on individual layers to be removed prior to processing.Customer Name:Date:Operator:CSR:Job Number:File Name:Page Size:File URL:200 Entin Road|Clifton,NewJersey 07014|p 973.470.8100|f

104、 973.470.9269|02-Mar-181009764ab_txt_T LasserAbbott Labs_1552CMYK8.5000 X 11.0000Mark is both a physicianwho specializes intreating chronic pain and apain patient himself.AbbottsBurstDR technology hashelped him manage his once-debilitating back pain.REDEFINING CHRONIC-PAIN RELIEFNeuromodulation is a

105、 new area ofexpertise for Abbott,and our advancedapproach to this technology has resultedin cutting-edge pain-relief devices.Recent advances in this area includeour Proclaim Elite recharge-freespinal-cord-stimulation system,whichfeatures Abbotts proprietary BurstDRstimulation.By emulating natural fi

106、ringpatterns of nerves in the brain,BurstDRcan give patients relief from both theirphysical pain and its associated emotionalsuffering.We also offer our Proclaim DRGneurostimulation system,designed todeliver therapy for focal chronic pain ofthe lower limbs.NEW HOPE FOR PEOPLE WITHMOVEMENT DISORDERSW

107、e are transforming the standard of carefor movement disorders with deep-brainstimulation products that can help treatand manage patients with Parkinsonsdisease and essential tremor.A leading product in this area is ourInfinity DBS,which delivers mildelectrical pulses to certain targets in thebrain t

108、o stimulate the structures involvedin motor control,while blocking theelectrical signals that cause involuntarymovements.ABBOTT TECHNOLOGYIMPROVES THE LIVES OFPEOPLE SUFFERING FROMCHRONIC PAIN ANDMOVEMENT DISORDERS.1.5 BILLIONpeople worldwide sufferfrom chronic pain.10DR.MARKMALONEAustin,Texas,USAA

109、B B O T T 2 0 1 7 A N N U A L R E P O R T1 91009764ab_txt.indd193/2/1811:40 AMPlease carefully do a final review of art and text to insure correctness and accuracy.Digital color representation may not be accurate,use actual Pantone color specifications.After clients final approval is received,SandyA

110、lexanderis not responsible for errors or legal compliance.Any changes made after receipt of clients final approval of art and text is clients responsibility.Die lines and call-outs exist on individual layers to be removed prior to processing.Customer Name:Date:Operator:CSR:Job Number:File Name:Page

111、Size:File URL:200 Entin Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|02-Mar-181009764ab_txt_T LasserAbbott Labs_1552CMYK29258.5000 X 11.00001,500Products in Abbottsportfolio,with morethan 400 currently indevelopment31manufacturingsites12developmentcentersBuilt on the foundation of the

112、trustconsumers and healthcare providershave in Abbott,our medicines businesscontinues to deliver excellent growthby meeting the need for high-quality,affordable medications in emergingmarkets.Weve built this business to be poweredglobally,but driven locally.Our globalscale provides a solid base to s

113、ustaincompetitiveness particularly when itcomes to manufacturing and innovation and our local decision making makes usnimble in fast-changing markets.We have a portfolio of more than 1,500products across multiple therapeuticareas,including gastroenterology,womens health,cardiometabolic,painmanagemen

114、t/central nervous system,respiratory,and influenza vaccines.And,within this offering,weve creatednew ways of using existing medicines,new delivery methods,new dosagecombinations,new indications,differentflavors,and enhanced packaging anddigital solutions that improve patientadherence.ABBOTTS MEDICIN

115、ESBUSINESS IS A UNIQUELYPOWERFUL GROWTH ENGINEFOCUSED ENTIRELY IN FAST-GROWING MARKETS.20A B B O T T 2 0 1 7 A N N U A L R E P O R T1009764ab_txt.indd203/2/1811:40 AMPlease carefully do a final review of art and text to insure correctness and accuracy.Digital color representation may not be accurate

116、,use actual Pantone color specifications.After clients final approval is received,SandyAlexanderis not responsible for errors or legal compliance.Any changes made after receipt of clients final approval of art and text is clients responsibility.Die lines and call-outs exist on individual layers to b

117、e removed prior to processing.Customer Name:Date:Operator:CSR:Job Number:File Name:Page Size:File URL:200 Entin Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|02-Mar-181009764ab_txt_T LasserAbbott Labs_1552CMYK292530258.5000 X 11.0000TRUSTED,BRANDED MEDICINESmeeting the needs of fast-gro

118、wing markets.DEPAKOTEDIVERSE PORTFOLIOBudi trusts our Depakotetablets to help control hisseizures,letting him focuson living his best possiblelife with his family.BUDI PUTRAJakarta,IndonesiaA B B O T T 2 0 1 7 A N N U A L R E P O R T2 11009764ab_txt.indd213/2/1811:40 AMPlease carefully do a final re

119、view of art and text to insure correctness and accuracy.Digital color representation may not be accurate,use actual Pantone color specifications.After clients final approval is received,SandyAlexanderis not responsible for errors or legal compliance.Any changes made after receipt of clients final ap

120、proval of art and text is clients responsibility.Die lines and call-outs exist on individual layers to be removed prior to processing.Customer Name:Date:Operator:CSR:Job Number:File Name:Page Size:File URL:200 Entin Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|02-Mar-181009764ab_txt_T

121、LasserAbbott Labs_1552CMYK29258.5000 X 11.0000SCIENCE-BASED NOURISHMENTat every stage of life,all around the world.ENSUREADVANCEELEVAINFANTFORMULA2 2A B B O T T 2 0 1 7 A N N U A L R E P O R T1009764ab_txt.indd223/2/1811:40 AMPlease carefully do a final review of art and text to insure correctness a

122、nd accuracy.Digital color representation may not be accurate,use actual Pantone color specifications.After clients final approval is received,SandyAlexanderis not responsible for errors or legal compliance.Any changes made after receipt of clients final approval of art and text is clients responsibi

123、lity.Die lines and call-outs exist on individual layers to be removed prior to processing.Customer Name:Date:Operator:CSR:Job Number:File Name:Page Size:File URL:200 Entin Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|02-Mar-181009764ab_txt_T LasserAbbott Labs_1552CMYK8.5000 X 11.0000En

124、sure Gold wheatflavor appealsto local tastes inVietnamAdult NutritionworldwidePediatric NutritionU.S.and manyinternational marketsGLOBAL LEADERSHIPHELPING GIVE CHILDREN ASTRONG STARTFor infants and toddlers,we makepowdered and ready-to-drink productsthat are trusted around the world tosupport health

125、y growth,address thespecial nutrition needs of childrenwho are ill,and help kids rehydrateafter diarrhea or vomiting.Beyondour Similac line of infant and toddlerformulas,we also offer PediaSure,our complete,balanced nutritionalsupplement that supports healthy growthand development,and Pedialyte,an o

126、ralelectrolyte solution specially formulatedto help prevent dehydration.HELPING ADULTS ACHIEVETHEIR HEALTH GOALSFor adults,Abbott has a broad portfolio ofproducts that includes modular products,which are added to existing formulasto address specific nutritional needs;supplemental nutrition to help f

127、ill gaps inthe diet;and oral nutritional supplementsand tube feeding,which provide a sourceof complete and balanced nutrition.Inaddition to our market-leading Ensurefamily of products,Abbott has developeda number of formulations that supportthe unique nutritional needs of peoplewith chronic illnesse

128、s,includingGlucerna,for people with diabetes,andNepro,for patients on dialysis.ABBOTTS PORTFOLIOOF NUTRITION PRODUCTSHELPS PEOPLE GET HEALTHYAND STAY THAT WAY.#1At 82,Elisa still has theenergy to keep doingthe things she loves.Sherelies on Ensure Advancenutritional supplementto support her strength

129、andmobility to help maintainher active lifestyle.ELISA FORTIBuenos Aires,ArgentinaA B B O T T 2 0 1 7 A N N U A L R E P O R T2 31009764ab_txt.indd233/2/1811:40 AMPlease carefully do a final review of art and text to insure correctness and accuracy.Digital color representation may not be accurate,use

130、 actual Pantone color specifications.After clients final approval is received,SandyAlexanderis not responsible for errors or legal compliance.Any changes made after receipt of clients final approval of art and text is clients responsibility.Die lines and call-outs exist on individual layers to be re

131、moved prior to processing.Customer Name:Date:Operator:CSR:Job Number:File Name:Page Size:File URL:200 Entin Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|02-Mar-181009764ab_txt_T LasserAbbott Labs_1552CMYK29258.5000 X 11.0000ENSURE#1 Doctor-recommendedbrand inthe U.S.PEDIALYTESpeciallyf

132、ormulated tohelp preventdehydrationEXPANDING OURIMPACTwith continual productimprovements.PURE BLISSFor parents whowant a non-GMO formula.Made withfresh milk fromgrass-fed cowsSIMILACThe first infantformula with2-FL Human MilkOligosaccharidesELISA FORTIand her grandsons24A B B O T T 2 0 1 7 A N N U A

133、 L R E P O R T1009764ab_txt.indd243/2/1811:40 AMPlease carefully do a final review of art and text to insure correctness and accuracy.Digital color representation may not be accurate,use actual Pantone color specifications.After clients final approval is received,SandyAlexanderis not responsible for

134、 errors or legal compliance.Any changes made after receipt of clients final approval of art and text is clients responsibility.Die lines and call-outs exist on individual layers to be removed prior to processing.Customer Name:Date:Operator:CSR:Job Number:File Name:Page Size:File URL:200 Entin Road|C

135、lifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|02-Mar-181009764ab_txt_T LasserAbbott Labs_1552CMYK292530258.5000 X 11.0000A BREAKTHROUGH ININFANT FORMULAHuman Milk Oligosaccharides(HMOs)are the third most abundant solidcomponent of breast milk after fat andcarbohydrates.They feed beneficialbac

136、teria in the gut,where 70%of theimmune system exists.Until recently,only breastfed babies have been able tobenefit from these important prebiotics.Today,thanks to Abbott scientists,these compounds are available in ourSimilac Pro-Advance and Similac Pro-Sensitive infant formulas.SCIENCE-BASED NUTRITI

137、ONIn 2017,Abbott introduced science-based nutrition drinks to help patientshave a better recovery from surgery.Research shows that staying nourishedin the days and hours prior to aprocedure can help patients prepare forand recover from surgery.New EnsureSurgery Immunonutrition Shake andEnsure Pre-Su

138、rgery Clear nutritiondrinks are designed for hospitalsimplementing surgical guidelines forenhancing patient recovery.GLUCERNALeading nutritionalproduct formulated tohelp people maintainhealthy glucose levelsand manage diabetesABBOTT DRAWS UPONCUTTING-EDGE RESEARCHTO DEVELOP MOREEFFECTIVE NUTRITIONAL

139、PRODUCTS.KEYPRODUCTLAUNCHESIN 201725Nutrition R&D centersworldwide let Abbottrespond quickly toregional differences inconsumer preferences,from taste to packaging5ENSURE SURGERY ANDPRE-SURGERY CLEARSpecifically designed tohelp patients prepare for,and recover from,surgeryA B B O T T 2 0 1 7 A N N U

140、A L R E P O R T2 51009764ab_txt.indd253/2/1811:40 AMPlease carefully do a final review of art and text to insure correctness and accuracy.Digital color representation may not be accurate,use actual Pantone color specifications.After clients final approval is received,SandyAlexanderis not responsible

141、 for errors or legal compliance.Any changes made after receipt of clients final approval of art and text is clients responsibility.Die lines and call-outs exist on individual layers to be removed prior to processing.Customer Name:Date:Operator:CSR:Job Number:File Name:Page Size:File URL:200 Entin Ro

142、ad|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|02-Mar-181009764ab_txt_T LasserAbbott Labs_1552CMYK29258.5000 X 11.0000ACCURATE,TIMELY INFORMATIONto better manage health and help improve outcomes.OUR EASIEST-TO-USEPOINT-OF-CARE TESTINGDEVICE YET2 6A B B O T T 2 0 1 7 A N N U A L R E P O R T

143、1009764ab_txt.indd263/2/1811:40 AMPlease carefully do a final review of art and text to insure correctness and accuracy.Digital color representation may not be accurate,use actual Pantone color specifications.After clients final approval is received,SandyAlexanderis not responsible for errors or leg

144、al compliance.Any changes made after receipt of clients final approval of art and text is clients responsibility.Die lines and call-outs exist on individual layers to be removed prior to processing.Customer Name:Date:Operator:CSR:Job Number:File Name:Page Size:File URL:200 Entin Road|Clifton,NewJers

145、ey 07014|p 973.470.8100|f 973.470.9269|02-Mar-181009764ab_txt_T LasserAbbott Labs_1552CMYK30258.5000 X 11.0000Abbott offers a wide range of diagnosticinstrument systems and tests forhospitals,reference labs,molecularlabs,blood banks,physician offices,and clinics.CORE LABORATORY ANDTRANSFUSION MEDICI

146、NEAbbott offers a comprehensive array ofimmunoassay and clinical-chemistryinstrument platforms,tests,and services.We are addressing our customers needfor greater efficiencies through the use ofanalytics,informatics,and automation.POINT OF CAREThe foundation of Abbotts point-of-caretesting business i

147、s the i-STAT System,ourmarket-leading portable blood analyzer,which can perform many of the mostcommonly ordered blood tests at thebedside,using only a few drops of blood.MOLECULARAbbott offers tests that analyze DNA andRNA at the molecular level,providingmore-accurate means to detect andmonitor dis

148、eases like HIV and hepatitis.INFORMATICSOur informatics solutions,such asSTARLIMS,help create smarter labswhile addressing the full spectrumof clinical needs,making actionableinformation available through mobiledevices in a secure,user-friendly manner.Born prematurely,Taonga has anumber of health is

149、sues that requireregular blood tests.His mother,Miranda,is grateful that Abbottsi-STATSystem uses only a few dropsof blood,which helps minimizeTaongas discomfort.11ABBOTTS PRODUCTS PROVIDEINFORMATION THAT HELPSPREVENT,DIAGNOSE,ANDTREAT A BROAD SPECTRUM OFHEALTH CONDITIONS.GLOBAL LEADERSHIPIN DIAGNOS

150、TICSLEADINGpoint-of-care platform in theUnited StatesBEST-IN-CLASSmolecular testsTAONGASHACKELLWhangarei,New ZealandIN BLOOD SCREENING#1A B B O T T 2 0 1 7 A N N U A L R E P O R T2 71009764ab_txt.indd273/2/18 3:42 PMPlease carefully do a final review of art and text to insure correctness and accurac

151、y.Digital color representation may not be accurate,use actual Pantone color specifications.After clients final approval is received,SandyAlexanderis not responsible for errors or legal compliance.Any changes made after receipt of clients final approval of art and text is clients responsibility.Die l

152、ines and call-outs exist on individual layers to be removed prior to processing.Customer Name:Date:Operator:CSR:Job Number:File Name:Page Size:File URL:200 Entin Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|02-Mar-181009764ab_txt_p_14_15_27_T LasserAbbott Labs_1552CMYK292530258.5000 X

153、11.0000ALINITYA DIAGNOSTICSREVOLUTIONA unified,holistic familyof systems.CLINICAL CHEMISTRYAlinity cIMMUNOASSAYAlinity iHEMATOLOGYAlinity hs/hqBLOOD SCREENINGAlinity sMOLECULARAlinity mPOINT OF CAREi-STAT AlinityINFORMATICSAlinity PROALINITY FAMILY2 8A B B O T T 2 0 1 7 A N N U A L R E P O R T100976

154、4ab_txt.indd283/2/1811:40 AMPlease carefully do a final review of art and text to insure correctness and accuracy.Digital color representation may not be accurate,use actual Pantone color specifications.After clients final approval is received,SandyAlexanderis not responsible for errors or legal com

155、pliance.Any changes made after receipt of clients final approval of art and text is clients responsibility.Die lines and call-outs exist on individual layers to be removed prior to processing.Customer Name:Date:Operator:CSR:Job Number:File Name:Page Size:File URL:200 Entin Road|Clifton,NewJersey 070

156、14|p 973.470.8100|f 973.470.9269|02-Mar-181009764ab_txt_T LasserAbbott Labs_1552CMYK30258.5000 X 11.0000Todays healthcare systems face a hostof challenges that impact their abilityto deliver the fast and accurate resultsdoctors need.Theyre being asked tohandle unprecedented volumes of testson limite

157、d budgets,with limited staffand limited space.Abbotts new family of systems whichincludes next-generation instrumentsfor clinical chemistry,immunoassay,hematology,point of care,blood andplasma screening,and moleculardiagnostics will help lab professionalsand clinicians meet these challengesbetter th

158、an any technology availabletoday.Systems in the Alinity family share anumber of key attributes:they offerfeatures that align with the needs oftodays labs;they provide innovativesolutions to current and futurechallenges;theyre designed to beinterconnected and work togetherseamlessly while using less

159、space intodays smaller labs;and they havecommon software and hardwareplatforms,plus universal,intuitiveinterfaces that make them simplerto use.ALINITY OFFERS A MAJORLEAP FORWARD INTERMS OF RELIABILITY,COST,CAPACITY,SPACEEFFICIENCY,AND EASEOF USE.Fueled By INNOVATIVE PossibilitiesWorking in UNITY To

160、Deliver ResultsALIGNED With Customer GoalsGAME-CHANGINGTECHNOLOGYAlinity is a total enterprise solution designed tohelp hospitals and diagnostic laboratories achievemeasurably better healthcare performance.A B B O T T 2 0 1 7 A N N U A L R E P O R T2 91009764ab_txt.indd293/2/1811:40 AMPlease careful

161、ly do a final review of art and text to insure correctness and accuracy.Digital color representation may not be accurate,use actual Pantone color specifications.After clients final approval is received,SandyAlexanderis not responsible for errors or legal compliance.Any changes made after receipt of

162、clients final approval of art and text is clients responsibility.Die lines and call-outs exist on individual layers to be removed prior to processing.Customer Name:Date:Operator:CSR:Job Number:File Name:Page Size:File URL:200 Entin Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|02-Mar-18

163、1009764ab_txt_T LasserAbbott Labs_1552CMYK30258.5000 X 11.0000IMPROVINGACCESS TO CAREwith our newly expandedoffering in rapid diagnostics.DELIVERING FAST,RELIABLE ANDACTIONABLE INFORMATIONRapid diagnostic testing can give doctors the insightsthey need in minutes to deliver the right care,atthe right

164、 time.Abbott is the world leader in point-of-care testing,with a targeted portfolio of systems andtests designed to improve the overall quality of careand help our customers deliver better clinical andeconomic healthcare outcomes.In 2017,wedelivered more than one billion tests to healthcareprofessio

165、nals and patients around the world.Abbott also offers drug testing and services thatallow for informed decisions by employers.OUR RAPIDTESTS FOR HIVHAVE BEEN ANIMPORTANTTOOL IN THEFIGHT AGAINSTAIDS AROUNDTHE WORLD.FOCUSED IN THREE KEY AREASINFECTIOUS DISEASECARDIOMETABOLICTOXICOLOGY3 0A B B O T T 2

166、0 1 7 A N N U A L R E P O R T1009764ab_txt.indd303/2/1811:40 AMPlease carefully do a final review of art and text to insure correctness and accuracy.Digital color representation may not be accurate,use actual Pantone color specifications.After clients final approval is received,SandyAlexanderis not

167、responsible for errors or legal compliance.Any changes made after receipt of clients final approval of art and text is clients responsibility.Die lines and call-outs exist on individual layers to be removed prior to processing.Customer Name:Date:Operator:CSR:Job Number:File Name:Page Size:File URL:2

168、00 Entin Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|02-Mar-181009764ab_txt_T LasserAbbott Labs_1552CMYK30258.5000 X 11.0000Estimated percentagechange in the numberof people with diabetes2000-2030 12DIABETES+114%Adults worldwide arenewly diagnosed withchronic pain each year 14CHRONIC

169、PAIN1 in 10Global prevalent casesof cardiovascular disease 13CARDIOVASCULARDISEASE400MProjected change in size ofemerging pharmaceuticalmarkets 2015-2025 15EMERGING-MARKETPHARMACEUTICALS+100%FUTUREABBOTTWere shaping Abbott for long-term growth bybuilding significant positions in those areas wherethe

170、 need for new solutions is greatest.GROWING WORLDWIDE NEEDS3 11009764ab_txt.indd313/5/18 9:21 AMPlease carefully do a final review of art and text to insure correctness and accuracy.Digital color representation may not be accurate,use actual Pantone color specifications.After clients final approval

171、is received,SandyAlexanderis not responsible for errors or legal compliance.Any changes made after receipt of clients final approval of art and text is clients responsibility.Die lines and call-outs exist on individual layers to be removed prior to processing.Customer Name:Date:Operator:CSR:Job Numb

172、er:File Name:Page Size:File URL:200 Entin Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|05-Mar-181009764ab_txt_p31_T LasserAbbott Labs_1552CMY3025PANTONE 3025_sp8.5000 X 11.000033Consolidated Statement of Earnings34 Consolidated Statement ofComprehensive Income35Consolidated Statement o

173、f Cash Flows36 Consolidated Balance Sheet38 Consolidated Statement ofShareholders Investment39 Notes to ConsolidatedFinancial Statements58 Management Report on InternalControl Over Financial Reporting58 Report of Independent RegisteredPublic Accounting Firm59 Report of Independent RegisteredPublic A

174、ccounting Firm60 Financial Instruments andRisk Management61Financial Review75Performance Graph76Summary of Selected Financial Data77Directors and Corporate Officers78Shareholder and Corporate Information2017FINANCIALREPORT32A B B O T T 2 0 1 7 A N N U A L R E P O R T1009764ab_txt.indd323/2/1811:40 A

175、MPlease carefully do a final review of art and text to insure correctness and accuracy.Digital color representation may not be accurate,use actual Pantone color specifications.After clients final approval is received,SandyAlexanderis not responsible for errors or legal compliance.Any changes made af

176、ter receipt of clients final approval of art and text is clients responsibility.Die lines and call-outs exist on individual layers to be removed prior to processing.Customer Name:Date:Operator:CSR:Job Number:File Name:Page Size:File URL:200 Entin Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470

177、.9269|02-Mar-181009764ab_txt_T LasserAbbott Labs_1552CMK30258.5000 X 11.00003 3A B B O T T 2 0 1 7 A N N U A L R E P O R TYear Ended December 31201720162015Net Sales$27,390$20,853$20,405Cost of products sold,excluding amortization of intangible assets12,3379,0248,747Amortization of intangible assets

178、1,975550601Research and development2,2351,4221,405Selling,general and administrative9,1176,6726,785Total Operating Cost and Expenses25,66417,66817,538Operating Earnings1,7263,1852,867Interest expense904431163Interest income(124)(99)(105)Net foreign exchange(gain)loss(34)495(93)Other(income)expense,n

179、et(1,251)945(281)Earnings from Continuing Operations Before Taxes2,2311,4133,183Taxes on Earnings from Continuing Operations1,878350577Earnings from Continuing Operations3531,0632,606Earnings from Discontinued Operations,net of taxes12432165Gain on sale of Discontinued Operations,net of taxes161,752

180、Net Earnings from Discontinued Operations,net of taxes1243371,817Net Earnings$477$1,400$4,423Basic Earnings Per Common ShareContinuing Operations$0.20$0.71$1.73Discontinued Operations0.070.231.21Net Earnings$0.27$0.94$2.94Diluted Earnings Per Common ShareContinuing Operations$0.20$0.71$1.72Discontin

181、ued Operations0.070.231.20Net Earnings$0.27$0.94$2.92Average Number of Common Shares Outstanding Used for BasicEarnings Per Common Share1,7401,4771,496Dilutive Common Stock Options9610Average Number of Common Shares Outstanding Plus DilutiveCommon Stock Options1,7491,4831,506Outstanding Common Stock

182、 Options Having No Dilutive Effect51The accompanying notes to consolidated financial statements are an integral part of this statement.CONSOLIDATED STATEMENT OF EARNINGS(in millions except per share data)1009764ab_fin.indd333/1/18 4:10 PMPlease carefully do a final review of art and text to insure c

183、orrectness and accuracy.Digital color representation may not be accurate,use actual Pantone color specifications.After clients final approval is received,SandyAlexanderis not responsible for errors or legal compliance.Any changes made after receipt of clients final approval of art and text is client

184、s responsibility.Die lines and call-outs exist on individual layers to be removed prior to processing.Customer Name:Date:Operator:CSR:Job Number:File Name:Page Size:File URL:200 Entin Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|01-Mar-181009764ab_fin_T LasserAbbott Labs_1552K29258.500

185、0 X 11.00003 4A B B O T T 2 0 1 7 A N N U A L R E P O R TCONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME(in millions)Year Ended December 31201720162015Net Earnings$477$1,400$4,423Foreign currency translation gain(loss)adjustments1,365(130)(2,013)Net actuarial gains(losses)and prior service cost and c

186、redits and amortizationof net actuarial losses and prior service cost and credits,net of taxes of$(61)in 2017,$(125)in 2016 and$101 in 2015(243)(326)252Unrealized gains(losses)on marketable equity securities,net of taxes of$(76)in 2017,$(28)in 2016 and$104 in 201564(134)64Net(losses)gains on derivat

187、ive instruments designated as cash flow hedges,net of taxes of$(43)in 2017,$(4)in 2016 and$(9)in 2015(134)(15)(35)Other Comprehensive Income(Loss)1,052(605)(1,732)Comprehensive Income$1,529$795$2,691Supplemental Accumulated Other Comprehensive Income(Loss)Information,net of tax as of December31:Cumu

188、lative foreign currency translation(loss)adjustments$(3,452)$(4,959)$(4,829)Net actuarial(losses)and prior service(cost)and credits(2,521)(2,284)(1,958)Cumulative unrealized(losses)gains on marketable equity securities(5)(69)65Cumulative(losses)gains on derivative instruments designated ascash flow

189、hedges(84)4964Accumulated other comprehensive income(loss)$(6,062)$(7,263)$(6,658)The accompanying notes to consolidated financial statements are an integral part of this statement.1009764ab_fin.indd343/1/18 4:10 PMPlease carefully do a final review of art and text to insure correctness and accuracy

190、.Digital color representation may not be accurate,use actual Pantone color specifications.After clients final approval is received,SandyAlexanderis not responsible for errors or legal compliance.Any changes made after receipt of clients final approval of art and text is clients responsibility.Die li

191、nes and call-outs exist on individual layers to be removed prior to processing.Customer Name:Date:Operator:CSR:Job Number:File Name:Page Size:File URL:200 Entin Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|01-Mar-181009764ab_fin_T LasserAbbott Labs_1552K29258.5000 X 11.00003 5A B B O T

192、 T 2 0 1 7 A N N U A L R E P O R TCONSOLIDATED STATEMENT OF CASH FLOWS(in millions)Year Ended December 31201720162015Cash Flow From(Used in)Operating Activities:Net earnings$477$1,400$4,423Adjustments to reconcile earnings to net cash from operating activitiesDepreciation1,046803871Amortization of i

193、ntangible assets1,975550601Sharebased compensation406310292Impact of currency devaluation480Amortization of inventory stepup907Investing and financing(gains)losses,net4786(18)Amortization of bridge financing fees5165Gains on sale of businesses(1,163)(25)(2,840)Mylan N.V.equity investment adjustment9

194、47Gain on sale of Mylan N.V.shares(45)(207)Trade receivables(207)(177)(171)Inventories249(98)(257)Prepaid expenses and other assets10911357Trade accounts payable and other liabilities615(652)(742)Income taxes1,149(699)957Net Cash From Operating Activities5,5703,2032,966Cash Flow From(Used in)Investi

195、ng Activities:Acquisitions of property and equipment(1,135)(1,121)(1,110)Acquisitions of businesses and technologies,net of cash acquired(17,183)(80)(235)Proceeds from business dispositions6,04225230Proceeds from the sale of Mylan N.V.shares2,7042,290Purchases of investment securities(210)(2,823)(4,

196、933)Proceeds from sales of investment securities1293,7094,112Other354252Net Cash From(Used in)Investing Activities(9,618)(248)406Cash Flow From(Used in)Financing Activities:Proceeds from issuance of(repayments of)shortterm debt and other(1,034)(1,767)(1,281)Proceeds from issuance of longterm debt an

197、d debt with maturitiesover 3months6,74214,9342,485Repayments of longterm debt and debt with maturities over 3months(8,650)(12)(57)Payment of bridge financing fees(170)Purchase of Alere preferred stock(710)Acquisition and contingent consideration payments related to businessacquisitions(13)(25)(17)Pu

198、rchases of common shares(117)(522)(2,237)Proceeds from stock options exercised350248314Dividends paid(1,849)(1,539)(1,443)Net Cash From(Used in)Financing Activities(5,281)11,147(2,236)Effect of exchange rate changes on cash and cash equivalents116(483)(198)Net(Decrease)Increase in Cash and Cash Equi

199、valents(9,213)13,619938Cash and Cash Equivalents,Beginning of Year18,6205,0014,063Cash and Cash Equivalents,End of Year$9,407$18,620$5,001Supplemental Cash Flow Information:Income taxes paid$570$620$631Interest paid917181166The accompanying notes to consolidated financial statements are an integral

200、part of this statement.1009764ab_fin.indd353/1/18 4:10 PMPlease carefully do a final review of art and text to insure correctness and accuracy.Digital color representation may not be accurate,use actual Pantone color specifications.After clients final approval is received,SandyAlexanderis not respon

201、sible for errors or legal compliance.Any changes made after receipt of clients final approval of art and text is clients responsibility.Die lines and call-outs exist on individual layers to be removed prior to processing.Customer Name:Date:Operator:CSR:Job Number:File Name:Page Size:File URL:200 Ent

202、in Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|01-Mar-181009764ab_fin_T LasserAbbott Labs_1552K29258.5000 X 11.00003 6A B B O T T 2 0 1 7 A N N U A L R E P O R TDecember3120172016AssetsCurrent Assets:Cash and cash equivalents$9,407$18,620Investments,primarily bank time deposits and U.

203、S.treasury bills203155Trade receivables,less allowances of2017:$294;2016:$2505,2493,248Inventories:Finished products2,3391,624Work in process472294Materials790516Total inventories3,6012,434Other prepaid expenses and receivables1,6671,806Current assets held for disposition20513Total Current Assets20,

204、14726,776Investments8832,947Property and Equipment,at Cost:Land526408Buildings3,6132,602Equipment10,3948,394Construction in progress73296215,26512,366Less:accumulated depreciation and amortization7,6586,661Net Property and Equipment7,6075,705Intangible Assets,net of amortization21,4734,539Goodwill24

205、,0207,683Deferred Income Taxes and Other Assets1,9442,263Noncurrent Assets Held for Disposition1762,753$76,250$52,666The accompanying notes to consolidated financial statements are an integral part of this statement.CONSOLIDATED BALANCE SHEET(dollars in millions)1009764ab_fin.indd363/1/18 4:10 PMPle

206、ase carefully do a final review of art and text to insure correctness and accuracy.Digital color representation may not be accurate,use actual Pantone color specifications.After clients final approval is received,SandyAlexanderis not responsible for errors or legal compliance.Any changes made after

207、receipt of clients final approval of art and text is clients responsibility.Die lines and call-outs exist on individual layers to be removed prior to processing.Customer Name:Date:Operator:CSR:Job Number:File Name:Page Size:File URL:200 Entin Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.926

208、9|01-Mar-181009764ab_fin_T LasserAbbott Labs_1552K29258.5000 X 11.00003 7A B B O T T 2 0 1 7 A N N U A L R E P O R TDecember3120172016Liabilities and Shareholders InvestmentCurrent Liabilities:Shortterm borrowings$206$1,322Trade accounts payable2,4021,178Salaries,wages and commissions1,187752Other a

209、ccrued liabilities3,8112,581Dividends payable489391Income taxes payable309188Current portion of longterm debt5083Current liabilities held for disposition245Total Current Liabilities8,9126,660Longterm Debt27,21020,681Postemployment obligations and other longterm liabilities9,0304,549Noncurrent liabil

210、ities held for disposition59Commitments and ContingenciesShareholders Investment:Preferred shares,one dollar par valueAuthorized1,000,000 shares,none issuedCommon shares,without par valueAuthorized2,400,000,000 sharesIssued at stated capital amountShares:2017:1,965,908,188;2016:1,707,475,45523,20613

211、,027Common shares held in treasury,at costShares:2017:222,305,719;2016:234,606,250(10,225)(10,791)Earnings employed in the business23,97825,565Accumulated other comprehensive income(loss)(6,062)(7,263)Total Abbott Shareholders Investment30,89720,538Noncontrolling Interests in Subsidiaries201179Total

212、 Shareholders Investment31,09820,717$76,250$52,666The accompanying notes to consolidated financial statements are an integral part of this statement.CONSOLIDATED BALANCE SHEET(dollars in millions)1009764ab_fin.indd373/1/18 4:10 PMPlease carefully do a final review of art and text to insure correctne

213、ss and accuracy.Digital color representation may not be accurate,use actual Pantone color specifications.After clients final approval is received,SandyAlexanderis not responsible for errors or legal compliance.Any changes made after receipt of clients final approval of art and text is clients respon

214、sibility.Die lines and call-outs exist on individual layers to be removed prior to processing.Customer Name:Date:Operator:CSR:Job Number:File Name:Page Size:File URL:200 Entin Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|01-Mar-181009764ab_fin_T LasserAbbott Labs_1552K29258.5000 X 11.0

215、0003 8A B B O T T 2 0 1 7 A N N U A L R E P O R TYear Ended December 31201720162015Common Shares:Beginning of YearShares:2017:1,707,475,455;2016:1,702,017,390;2015:1,694,929,949$13,027$12,734$12,383Issued under incentive stock programsShares:2017:8,834,924;2016:5,458,065;2015:7,087,441242222289Issue

216、d for St.Jude Medical acquisitionShares:2017:249,597,8099,835Sharebased compensation406311292Issuance of restricted stock awards(304)(240)(230)End of YearShares:2017:1,965,908,188;2016:1,707,475,455;2015:1,702,017,390$23,206$13,027$12,734Common Shares Held in Treasury:Beginning of YearShares:2017:23

217、4,606,250;2016:229,352,338;2015:186,894,515$(10,791)$(10,622)$(8,678)Issued under incentive stock programsShares:2017:8,696,320;2016:5,398,469;2015:5,381,586400250250Issued for St.Jude Medical acquisitionShares:2017:3,906,848180PurchasedShares:2017:302,637;2016:10,652,381;2015:47,839,409(14)(419)(2,

218、194)End of YearShares:2017:222,305,719;2016:234,606,250;2015:229,352,338$(10,225)$(10,791)$(10,622)Earnings Employed in the Business:Beginning of Year$25,565$25,757$22,874Net earnings4771,4004,423Cash dividends declared on common shares(per share2017:$1.075;2016:$1.045;2015:$0.98)(1,947)(1,547)(1,46

219、4)Effect of common and treasury share transactions(117)(45)(76)End of Year$23,978$25,565$25,757Accumulated Other Comprehensive Income(Loss):Beginning of Year$(7,263)$(6,658)$(5,053)Business dispositions/separation149127Other comprehensive income(loss)1,052(605)(1,732)End of Year$(6,062)$(7,263)$(6,6

220、58)Noncontrolling Interests in Subsidiaries:Beginning of Year$179$115$113Noncontrolling Interests share of income,business combinations,net of distributions and share repurchases22642End of Year$201$179$115The accompanying notes to consolidated financial statements are an integral part of this state

221、ment.CONSOLIDATED STATEMENT OF SHAREHOLDERS INVESTMENT(in millions except shares and per share data)1009764ab_fin.indd383/1/18 4:10 PMPlease carefully do a final review of art and text to insure correctness and accuracy.Digital color representation may not be accurate,use actual Pantone color specif

222、ications.After clients final approval is received,SandyAlexanderis not responsible for errors or legal compliance.Any changes made after receipt of clients final approval of art and text is clients responsibility.Die lines and call-outs exist on individual layers to be removed prior to processing.Cu

223、stomer Name:Date:Operator:CSR:Job Number:File Name:Page Size:File URL:200 Entin Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|01-Mar-181009764ab_fin_T LasserAbbott Labs_1552K29258.5000 X 11.00003 9A B B O T T 2 0 1 7 A N N U A L R E P O R TNOTES TO CONSOLIDATED FINANCIAL STATEMENTSNOTE

224、1SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESNature of BusinessAbbotts principal business is the discovery,development,manufacture and sale of a broad line of health careproducts.Changes in PresentationIn September 2016,Abbott announcedthat it had entered into an agreement to sell Abbott Medical Optic

225、s(AMO),its vision care business,to Johnson&Johnson.The transaction closed in February 2017.The operating results of AMO upto the date of sale were reported as part of continuing operationsas AMO did not qualify for reporting as a discontinued operation.The assets and liabilities of AMO are reported

226、as held for disposition in Abbotts Consolidated Balance Sheet at December 31,2016.On February 27,2015,Abbott completed the sale of its developedmarkets branded generics pharmaceuticals business to Mylan Inc.(Mylan)for equity ownership of a newly formed entity that combined Mylans existing business a

227、nd Abbotts developed marketspharmaceuticals business.On February 10,2015,Abbott completedthe sale of its animal health business to Zoetis Inc.The historicaloperating results of these two businesses up to the date of saleareexcluded from Earnings from Continuing Operations and arepresented on the Ear

228、nings from Discontinued Operations,net oftaxes line in Abbotts Consolidated Statement of Earnings.Thecashflowsof these businesses are included in AbbottsConsolidatedStatement of Cash Flows up to the date of disposition.See Note2Discontinued Operations for additional information.Basis of Consolidatio

229、nThe consolidated financial statementsinclude the accounts of the parent company and subsidiaries,afterelimination of intercompany transactions.Use of EstimatesThe consolidated financial statements havebeenprepared in accordance with generally accepted accountingprinciples in the United States and n

230、ecessarily include amountsbased on estimates and assumptions by management.Actualresults could differ from those amounts.Significant estimatesinclude amounts for sales rebates;income taxes;pension andother postemployment benefits,including certain asset valuesthat are based on significant unobservab

231、le inputs;valuation ofintangible assets;litigation;derivative financial instruments;and inventory and accounts receivable exposures.ForeignCurrency TranslationThestatements of earnings of foreignsubsidiaries whose functional currencies are other than the U.S.dollar are translated into U.S.dollars us

232、ing average exchange ratesfor the period.The net assets of foreign subsidiaries whose functional currencies are other than the U.S.dollar are translated intoU.S.dollars using exchange rates as of the balance sheet date.TheU.S.dollar effects that arise from translating the net assets of thesesubsidia

233、ries at changing rates are recorded in the foreign currencytranslation adjustment account,which is included in equity as acomponent of Accumulated other comprehensive income(loss).Transaction gains and losses are recorded on the Net foreignexchange(gain)loss lineof the Consolidated Statement ofEarni

234、ngs.Revenue RecognitionRevenue from product sales is recognizedupon passage of title and risk of loss to customers.Provisions fordiscounts,rebates and sales incentives to customers,and returnsand other adjustments are provided for in the period the relatedsales are recorded.Sales incentives to custo

235、mers are not material.Historical data is readily available and reliable,and is used forestimating the amount of the reduction in gross sales.Revenuefrom the launch of a new product,from an improved version of anexisting product,or for shipments in excess of a customers normal requirements are record

236、ed when the conditions noted aboveare met.In those situations,management records a returns reservefor such revenue,if necessary.In certain of Abbotts businesses,primarily within diagnostics and medical optics,prior to its divestiture,Abbott participates in selling arrangements that includemultiple d

237、eliverables(e.g.,instruments,reagents,procedures,andservice agreements).Under these arrangements,Abbott recognizes revenue upon delivery of the product or performance of theservice and allocates the revenue based on the relative sellingprice of each deliverable,which is based primarily on vendorspec

238、ific objective evidence.Sales of product rights for marketableproducts are recorded as revenue upon disposition of the rights.Revenue from license of product rights,or for performance ofresearch or selling activities,is recorded over the periods earned.In May 2014,the Financial Accounting Standards

239、Board(FASB)issued Accounting Standards Update(ASU)201409,Revenue fromContracts with Customers,which provides a single comprehensivemodel for accounting for revenue from contracts with customersandwillsupersedemostexisting revenue recognition guidance.Thestandard becomes effective for Abbott in the f

240、irst quarter of 2018.Abbotts revenues are primarily comprised of product sales.Abbottcompleted a thorough evaluation of the new standard including adetailed review of Abbotts revenue streams and contracts.Abbottdoes not expect the adoption of the new standard to have a materialimpact on its consolid

241、ated financial statements.Abbott will use themodified retrospective method to adopt this standard.IncomeTaxesDeferred income taxesare provided for the tax effectof differences between the tax bases of assets and liabilities andtheir reported amounts in the financial statements at the enactedstatutor

242、y rate to be in effect when the taxes are paid.No additionalincome taxes have been provided for any remaining undistributedforeign earnings not subject to the transition tax related to the U.S.Tax Cuts and Jobs Act,or any additional outside basis differencesthat exist,as these amounts continue to be

243、 indefinitely reinvestedin foreign operations.Interest and penalties on income tax obligations are included in taxes on income.EarningsPer ShareUnvestedrestrictedstockunitsandawardsthatcontainnonforfeitable rights to dividends are treatedasparticipatingsecuritiesandare included in the computation of

244、 earnings pershare under the twoclassmethod.Under the twoclassmethod,netearnings are allocated between common shares and participatingsecurities.Earnings from Continuing Operations allocated to common shares in 2017,2016 and 2015 were$346 million,$1.057 billionand$2.595 billion,respectively.Net earn

245、ings allocated to commonshares in 2017,2016 and 2015 were$468 million,$1.393billion and$4.403 billion,respectively.Pension and Post-Employment BenefitsAbbott accrues for theactuarially determined cost of pension and postemploymentbenefits over the service attribution periods of the employees.Abbott

246、must develop longterm assumptions,the most significantof which are the health care cost trend rates,discount rates and theexpected return on plan assets.Differences between the expectedlongterm return on plan assets and the actual return are amortizedover a fiveyear period.Actuarial losses and gains

247、 are amortizedover the remaining service attribution periods of the employeesunder the corridor method.Fair Value MeasurementsFor assets and liabilities that aremeasured using quoted prices in active markets,total fair valueisthe published market price per unit multiplied by the numberofunits held w

248、ithout consideration of transaction costs.Assetsand liabilities that are measured using significant other observableinputs are valued by reference to similar assets or liabilities,1009764ab_fin.indd393/1/18 4:10 PMPlease carefully do a final review of art and text to insure correctness and accuracy.

249、Digital color representation may not be accurate,use actual Pantone color specifications.After clients final approval is received,SandyAlexanderis not responsible for errors or legal compliance.Any changes made after receipt of clients final approval of art and text is clients responsibility.Die lin

250、es and call-outs exist on individual layers to be removed prior to processing.Customer Name:Date:Operator:CSR:Job Number:File Name:Page Size:File URL:200 Entin Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|01-Mar-181009764ab_fin_T LasserAbbott Labs_1552K29258.5000 X 11.00004 0A B B O T

251、T 2 0 1 7 A N N U A L R E P O R TNOTES TO CONSOLIDATED FINANCIAL STATEMENTSadjusted for contract restrictions and other terms specific to thatasset or liability.For these items,a significant portion of fair valueis derived by reference to quoted prices of similar assets or liabilities in active mark

252、ets.For all remaining assets and liabilities,fairvalue is derived using a fair value model,such as a discounted cashflow model or BlackScholes model.Purchased intangible assetsare recorded at fair value.The fair value of significant purchasedintangible assets is based on independent appraisals.Abbot

253、t usesadiscounted cash flow model to value intangible assets.Thediscounted cash flow model requires assumptions about the timingand amount of future net cash flows,risk,the cost of capital,terminal values and market participants.Intangible assets are reviewedfor impairment on a quarterly basis.Goodw

254、ill and indefinitelivedintangible assets are tested for impairment at least annually.Share-Based CompensationThe fair value of stock options andrestricted stock awards and units are amortized over their requisite service period,which could be shorter than the vesting periodif an employee is retireme

255、nt eligible,with a charge to compensation expense.In March 2016,the FASB issued ASU 201609,Improvements toEmployee Share-Based Payment Accounting.ASU 201609 modifies several aspects of the accounting for sharebased paymenttransactions,including the accounting for income taxes andclassification on th

256、e statement of cash flows.Abbott adopted thestandard in the first quarter of 2017 and the following changeswere made to the presentation of Abbotts financial statements:All excess tax benefits or tax deficiencies are now recognizedasincome tax benefit or expense as applicable.Previously,Abbott recor

257、ded the benefits to Shareholders Investment.Thetax benefit recorded in Abbotts Consolidated StatementofEarnings for 2017 was$120 million.The standard does notpermit retrospective presentation of this benefit in prior years.The tax benefit or deficiency is required to be classified as anoperating act

258、ivity in the statement of cash flows.Previously,itwas required to be classified within financing activities.Abbotthas adopted this standard on a prospective basis and has notrevised the classification of the excess tax benefit in the prioryears Consolidated Statement of Cash Flows.LitigationAbbott a

259、ccounts for litigation losses in accordancewith FASB ASC No.450,“Contingencies.”Under ASC No.450,loss contingency provisions are recorded for probable losses atmanagements best estimate of a loss,or when a best estimatecannot be made,a minimum loss contingency amount is recorded.Legal fees are recor

260、ded as incurred.Cash,Cash Equivalents and InvestmentsCash equivalents consistof bank time deposits,U.S.government securities money marketfunds and U.S.treasury bills with original maturities of threemonths or less.Abbott holds certain investments with a carryingvalue of approximately$235 million tha

261、t are accounted for underthe equity method of accounting.Investments held in a rabbi trustare accounted for as trading securities.All other investments inmarketable equity securities are classified as availableforsale andare recorded at fair value with any unrealized holding gains orlosses,net of ta

262、x,included in Accumulated other comprehensiveincome(loss).Investments in equity securities that are not tradedon publicstockexchangesare recordedatcost.Investments in debtsecurities are classified as heldtomaturity,as management hasboth the intent and ability to hold these securities to maturity,and

263、are reported at cost,net of any unamortized premium or discount.Income relating to these securities is reported as interest income.Abbott reviews the carrying value of investments each quarter todetermine whether an other than temporary decline in fair valueexists.Abbott considers factors affecting

264、the investee,factorsaffecting the industry the investee operates in and general equitymarket trends.Abbott considers the length of time an investmentsfair value has been below carrying value and the nearterm prospects for recovery to carrying value.When Abbott determines thatan other than temporary

265、decline has occurred,the investment iswritten down with a charge to Other(income)expense,net.Trade Receivable ValuationsAccounts receivable are stated attheir net realizable value.The allowance against gross tradereceivables reflects the best estimate of probable losses inherentin the receivables po

266、rtfolio determined on the basis of historicalexperience,specific allowances for known troubled accounts andother currently available information.Accounts receivable arecharged off after all reasonable means to collect the full amount(including litigation,where appropriate)have been exhausted.Invento

267、riesInventoriesarestatedatthelowerofcost(firstin,firstout basis)or market.Cost includes material and conversion costs.Property and EquipmentDepreciation and amortization areprovided on a straightline basis over the estimated useful lives ofthe assets.The following table shows estimated useful lives

268、ofproperty and equipment:ClassificationEstimated Useful LivesBuildings10 to 50 years(average 27 years)Equipment3 to 20 years(average 11 years)Product LiabilityAbbott accrues for product liability claimswhen it is probable that a liability has been incurred and theamount of the liability can be reaso

269、nably estimated based onexisting information.The liabilities are adjusted quarterly asadditional information becomes available.Receivables for insurance recoveries for product liability claims are recorded as assets,on an undiscounted basis,when it is probable that a recoverywill be realized.Product

270、 liability losses are selfinsured.Research and Development CostsInternal research and development costs are expensed as incurred.Clinical trial costs incurredby third parties are expensed as the contracted work is performed.Wherecontingentmilestonepaymentsareduetothirdpartiesunderresearch and develo

271、pment arrangements,the milestone paymentobligations are expensed when the milestone results are achieved.Acquired In-Process and Collaborations Research and Development(IPR&D)The initial costs of rights to IPR&D projects obtainedinan asset acquisition are expensed as IPR&D unless the projecthas an a

272、lternative future use.These costs include initial paymentsincurred prior to regulatory approval in connection with researchand development collaboration agreements that provide rights todevelop,manufacture,market and/or sell pharmaceutical products.The fair value of IPR&D projects acquired in a busi

273、nesscombination are capitalized and accounted for as indefinitelivedintangible assets until completed and are then amortized over theremaining useful life.Collaborations are not significant.Concentration of Risk and GuaranteesDue to the nature of itsoperations,Abbott is not subject to significant co

274、ncentration risksrelating to customers,products or geographic locations.Productwarranties are not significant.1009764ab_fin.indd403/1/18 4:10 PMPlease carefully do a final review of art and text to insure correctness and accuracy.Digital color representation may not be accurate,use actual Pantone co

275、lor specifications.After clients final approval is received,SandyAlexanderis not responsible for errors or legal compliance.Any changes made after receipt of clients final approval of art and text is clients responsibility.Die lines and call-outs exist on individual layers to be removed prior to pro

276、cessing.Customer Name:Date:Operator:CSR:Job Number:File Name:Page Size:File URL:200 Entin Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|01-Mar-181009764ab_fin_T LasserAbbott Labs_1552K29258.5000 X 11.000041A B B O T T 2 0 1 7 A N N U A L R E P O R TNOTES TO CONSOLIDATED FINANCIAL STATEM

277、ENTSAbbott has no material exposures to offbalance sheet arrangements;no special purpose entities;nor activities that includenonexchangetraded contracts accounted for at fair value.Abbotthas periodically entered into agreements in the ordinary course ofbusiness,such as assignment of product rights,w

278、ith other companies,which has resulted in Abbott becoming secondarily liable forobligations that Abbott was previously primarily liable.SinceAbbott no longer maintains a business relationship with the otherparties,Abbott is unable to develop an estimate of the maximumpotential amount of future payme

279、nts,if any,under these obligations.Based upon past experience,the likelihood of paymentsunder these agreements is remote.Abbott periodically acquires abusiness or product rights in which Abbott agrees to pay contingent consideration based on attaining certain thresholds or basedon the occurrence of

280、certain events.NOTE 2DISCONTINUED OPERATIONSOn February 27,2015,Abbott completed the sale of its developedmarkets branded generics pharmaceuticals business to Mylan Inc.(Mylan)for 110 million ordinary shares(or approximately 22%)ofa newly formed entity(Mylan N.V.)that combined Mylans existingbusines

281、s and Abbotts developed markets branded generics pharmaceuticals business.Mylan N.V.is publicly traded.Historically,this business was included in Abbotts Established PharmaceuticalProducts segment.Abbott retained its branded generics pharmaceuticals business in emerging markets.At the date of closin

282、g,the110 million Mylan N.V.ordinary shares that Abbott received werevalued at$5.77 billion and Abbott recorded an aftertax gain on thesale of the business of approximately$1.6 billion.The shareholderagreement with Mylan N.V.includes voting and other restrictionsthat prevent Abbott from exercising si

283、gnificant influence over theoperating and financial policies of Mylan N.V.At the close of this transaction Abbott and Mylan entered intoa transition services agreement pursuant to which Abbott andMylan provided various back office support services to each otheron an interim transitional basis for up

284、 to 2 years.Certain serviceswere extended for an additional five to ten months.Charges byAbbott under this transition services agreement were recordedas a reduction of the costs to provide the respective service in theapplicable expense category in the Consolidated Statement ofEarnings.This transiti

285、on support did not constitute significantcontinuing involvement in Mylans operations.Abbott also enteredinto manufacturing supply agreements with Mylan related tocertain products,with the supply term ranging from 3 to 10 yearsand requiring a 2 year notice prior to termination.The cash flowsassociate

286、d with these transition services and manufacturing supply agreements are not expected to be significant,and therefore,these cash flows are not direct cash flows of the disposed component under Accounting Standards Codification 205.In April 2015,Abbott sold 40.25 million of the 110 million ordinarysh

287、ares of Mylan N.V.received in the sale of the developed marketsbranded generics pharmaceuticals business to Mylan.Abbottrecorded a pretax gain of$207 million on$2.29 billion in netproceeds from the sale of these shares.The gain is recognized inthe Other(income)expense line of the 2015 ConsolidatedSt

288、atement of Earnings.As a result of this sale,Abbotts ownershipinterest in Mylan N.V.decreased to approximately 14%.In 2017,Abbott sold 69.75 million ordinary shares of Mylan N.V.and received$2.704 billion in proceeds.Abbott recorded a$45 million gain from the sale of these ordinary shares in 2017,wh

289、ich was recognized in the Other(income)expense,net line ofthe Consolidated Statement of Earnings.Abbott no longer has anownership interest in Mylan N.V.On February 10,2015,Abbott completed the sale of its animalhealth business to Zoetis Inc.Abbott received cash proceeds of$230 million and reported a

290、n after tax gain on the sale of approximately$130 million.In the first quarter of 2016,Abbott receivedan additional$25 million of proceeds due to the expiration of aholdback agreement associated with the sale of this business andreported an aftertax gain of$16 million.As a result of the disposition

291、of the above businesses,the operatingresults of these businesses up to the date of sale are reported aspart of discontinued operations on the Earnings from DiscontinuedOperations,net of taxes line in the Consolidated Statement ofEarnings.Discontinued operations include an allocation of interest expe

292、nse assuming a uniform ratio of consolidated debt toequity for all of Abbotts historical operations.On January 1,2013,Abbott completed the separation of AbbVieInc.(AbbVie),which was formed to hold Abbotts researchbasedproprietary pharmaceuticals business.Abbott has retained allliabilities for all U.

293、S.federal and foreign income taxes on incomeprior to the separation,as well as certain nonincome taxes attributable to AbbVies business.AbbVie generally will be liable for allother taxes attributable to its business.The operating results of Abbotts developed markets brandedgenerics pharmaceuticals a

294、nd animal health businesses,as wellasthe income tax benefit related to the businesses transferredto AbbVie,which are being reported as discontinued operationsare as follows:(inmillions)Year Ended December31201720162015Net SalesDeveloped markets genericspharmaceuticals and animalhealth businesses$256

295、AbbVieTotal$256Earnings(Loss)Before TaxDeveloped markets genericspharmaceuticals and animalhealth businesses$15$(4)$13AbbVieTotal$15$(4)$13Net EarningsDeveloped markets genericspharmaceuticals and animalhealth businesses$15$3$62AbbVie1093183Total$124$321$65The net earnings of discontinued operations

296、 include incometaxbenefits of$109 million in 2017,$325 million in 2016 and$52 million in 2015.The tax benefits in 2017 and 2016 primarilyrelate to the resolution of various tax positions related to AbbViesoperations for years prior to the separation.2015 includes$48 million of tax benefits related t

297、o the resolution of various taxpositions related to prior years.1009764ab_fin.indd413/1/18 4:10 PMPlease carefully do a final review of art and text to insure correctness and accuracy.Digital color representation may not be accurate,use actual Pantone color specifications.After clients final approva

298、l is received,SandyAlexanderis not responsible for errors or legal compliance.Any changes made after receipt of clients final approval of art and text is clients responsibility.Die lines and call-outs exist on individual layers to be removed prior to processing.Customer Name:Date:Operator:CSR:Job Nu

299、mber:File Name:Page Size:File URL:200 Entin Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|01-Mar-181009764ab_fin_T LasserAbbott Labs_1552K29258.5000 X 11.000042A B B O T T 2 0 1 7 A N N U A L R E P O R TNOTES TO CONSOLIDATED FINANCIAL STATEMENTSThe sale of the developed markets branded

300、generics pharmaceuticals and animal health business in 2015 resulted in the recognitionof a pretax gain of$2.840 billion,tax expense of$1.088 billion andan after tax gain of$1.752 billion.The 2015 tax provision included$667 million of tax expense on certain prior year income earnedoutside the U.S.re

301、lated to the developed markets branded genericspharmaceuticals businesses that were not designated as permanently reinvested overseas.NOTE 3ASSETS AND LIABILITIES HELD FOR DISPOSITIONIn September 2016,Abbott announced that it entered into adefinitive agreement to sell Abbott Medical Optics(AMO),itsv

302、ision care business,to Johnson&Johnson for$4.325billion incash,subject to customary purchase price adjustments for cash,debt and working capital.The decision to sell AMO reflectedAbbotts proactive shaping of its portfolio in line with its strategicpriorities.In February 2017,Abbott completed the sal

303、e of AMO toJohnson&Johnson and recognized a pretax gain of$1.163 billionincluding working capital adjustments,which was reported in theOther(income)expense,net line of the Consolidated Statement ofEarnings in 2017.Abbott recorded an aftertax gain of$728 millionin 2017 related to the sale of AMO.The

304、operating results of AMOup to the date of sale continued to be included in Earnings fromcontinuing operations as the business did not qualify for reportingas discontinued operations.For 2017,2016 and 2015,the AMOearnings(losses)before taxes included in Abbotts consolidatedearnings were$(18)million,$

305、30million and$64 million,respectively.Assets and liabilities of AMO were classified as held fordisposition in Abbotts Consolidated Balance Sheet as ofDecember 31,2016.As discussed in Note 6Business Acquisitions,in conjunctionwith the acquisition of Alere Inc.(Alere),Abbott sold the TriageMeterPro ca

306、rdiovascular and toxicology business and the assetsand liabilities related to its Btype Natriuretic Peptide assay business run on Beckman Coulter analyzers to Quidel Corporation(Quidel).The legal transfer of certain assets and liabilities relatedto these businesses did not occur at the close of the

307、sale to Quideldue to,among other factors,the time required to transfer marketing authorizations and other regulatory requirements in variouscountries.Under the terms of the sale agreement with Abbott,Quidel is subject to the risks and entitled to the benefits generated by these operations and assets

308、.The assets and liabilitiespresented as held for disposition in the Consolidated BalanceSheet as of December 31,2017,primarily relate to the businessessold to Quidel.The following is a summary of the assets and liabilities held fordisposition as of December 31,2017 and 2016:(inmillions)December31201

309、72016Trade receivables,net$12$222Total inventories8240Prepaid expenses and other current assets51Current assets held for disposition20513Net property and equipment56247Intangible assets,net of amortization18529Goodwill1021,966Deferred income taxes and other assets11Noncurrent assets held for disposi

310、tion1762,753Total assets held for disposition$196$3,266Trade accounts payable$71Salaries,wages,commissions and other accruedliabilities174Current liabilities held for disposition245Postemployment obligations,deferred incometaxes and other longterm liabilities59Total liabilities held for disposition$

311、304NOTE 4SUPPLEMENTAL FINANCIAL INFORMATIONOther(income)expense,net,for 2017 includes a pretax gain of$1.163 billion related to the sale of AMO to Johnson&Johnson.See Note 3Assets and Liabilities Held for Disposition for furtherdetails.Other(income)expense,net,for 2016 includes expense of$947 millio

312、n to adjust Abbotts holding of Mylan N.V.ordinaryshares due to a decline in the fair value of the securities which wasconsidered by Abbott to be other than temporary.Other(income)expense,net,for 2015 primarily relates to a$207 million gain onthe sale of a portion of Abbotts position in Mylan N.V.sto

313、ck and$79 million of income resulting from a decrease in the fair valueofcontingent consideration related to a business acquisition.The detail of various balance sheet components is as follows:(inmillions)20172016Longterm Investments:Equity securities$797$2,906Other8641Total$883$2,947The decrease in

314、 longterm investments relates to the sale in 2017of the remaining ordinary shares of Mylan N.V.that Abbott held.Abbott sold 69.75 million ordinary shares of Mylan N.V.andreceived$2.704 billion in proceeds.Abbott recorded a$45 millionpretax gain in 2017 related to the sale of these ordinary shares,wh

315、ich was recognized in the Other(income)expense,net line ofthe Consolidated Statement of Earnings.As of December 31,2017,Abbott no longer has an ownership interest in Mylan N.V.1009764ab_fin.indd423/1/18 4:10 PMPlease carefully do a final review of art and text to insure correctness and accuracy.Digi

316、tal color representation may not be accurate,use actual Pantone color specifications.After clients final approval is received,SandyAlexanderis not responsible for errors or legal compliance.Any changes made after receipt of clients final approval of art and text is clients responsibility.Die lines a

317、nd call-outs exist on individual layers to be removed prior to processing.Customer Name:Date:Operator:CSR:Job Number:File Name:Page Size:File URL:200 Entin Road|Clifton,NewJersey 07014|p 973.470.8100|f 973.470.9269|01-Mar-181009764ab_fin_T LasserAbbott Labs_1552K29258.5000 X 11.00004 3A B B O T T 2

318、0 1 7 A N N U A L R E P O R TNOTES TO CONSOLIDATED FINANCIAL STATEMENTSAbbotts equity securities as of December 31,2017,include$363 million of investments in mutual funds that are held in arabbi trust and were acquired as part of the St.Jude Medical,Inc.(St.Jude Medical)business acquisition.These in

319、vestments,whichare specifically designated as available for the purposeofpaying benefits under a deferred compensation plan,are notavailable for general corporate purposes and are subject tocreditor claims in the event of insolvency.(inmillions)20172016Other Accrued Liabilities:Accrued rebates payab

320、le to government agencies$124$110Accrued other rebates(a)498296All other3,1892,175Total$3,811$2,581(a)Accrued wholesaler chargeback rebates of$178 million and$214 million at December31,2017and 2016,respectively,are netted in trade receivables because Abbotts customers are invoicedat a highercatalog

321、price but only remit to Abbott their contract price for the products.(inmillions)20172016Postemployment Obligations and Other LongtermLiabilities:Defined benefit pension plans and postemploymentmedicalanddentalplans forsignificantplans$2,169$2,154Deferred income taxes2,006356All other(b)4,8552,039To

322、tal$9,030$4,549(b)2017 includes approximately$835 million of net unrecognized tax benefits,as well asapproximately$100 million of acquisition consideration payable.2016 includes approximately$560 million of net unrecognized tax benefits,as well as approximately$130 million of acquisition considerati

323、on payable.Since January 2010,Venezuela has been designated as a highlyinflationary economy under U.S.GAAP.In 2014 and 2015,thegovernment of Venezuela operated multiple mechanisms toexchange bolivars into U.S.dollars.These mechanisms includedthe CENCOEX,SICAD,and SIMADI rates,which stood at 6.3,13.5

324、,and approximately 200,respectively,at December 31,2015.In 2015,Abbott continued to use the CENCOEX rate of 6.3Venezuelan bolivars to the U.S.dollar to report the results,financial position,and cash flows related to its operations in Venezuelasince Abbott continued to qualify for this exchange rate

325、to pay forthe import of various products into Venezuela.On February 17,2016,the Venezuelan government announcedthatthe threetier exchange rate system would be reduced to tworates renamed the DIPRO and DICOM rates.The DIPRO rate isthe official rate for food and medicine imports and was adjustedfrom 6

326、.3 to 10 bolivars per U.S.dollar.The DICOM rate is a floating market rate published daily by the Venezuelan central bank,which at the end of the first quarter of 2016 was approximately263bolivars per U.S.dollar.As a result of decreasing governmentapprovals to convert bolivars to U.S.dollars to pay f

327、or intercompany accounts,as well as the accelerating deterioration ofeconomic conditions in the country,Abbott concluded that it wasappropriate to move to the DICOM rate at the end of the firstquarter of 2016.As a result,Abbott recorded a foreign currencyexchange loss of$480 million in 2016 to reval

328、ue its net monetaryassets in Venezuela.Abbott is continuing to use the DICOM ratetoreport the results of operations and to remeasure net monetaryassets for Venezuela at the end of each quarter.As of December 31,2017,Abbotts investment in its Venezuelan operations was notsignificant.As a result,any a

329、dditional future foreign currencylosses related to Venezuela would not be material.NOTE 5ACCUMULATED OTHER COMPREHENSIVE INCOME(LOSS)The components of the changes in accumulated other comprehensive income(loss)from continuing operations,net of income taxes,are as follows:(inmillions)CumulativeForeig

330、n CurrencyTranslationAdjustmentsNet ActuarialLosses and PriorService Costs andCreditsCumulativeUnrealized Gains(Losses)onMarketable EquitySecuritiesCumulative Gains(Losses)onDerivativeInstrumentsDesignated as CashFlow HedgesTotalBalance at December 31,2015$(4,829)$(1,958)$65$64$(6,658)Other comprehe

331、nsive income(loss)beforereclassifications(130)(393)(1,109)41(1,591)(Income)loss amounts reclassified from accumulatedother comprehensive income(a)67975(56)986Net current period other comprehensive income(loss)(130)(326)(134)(15)(605)Balance at December 31,2016(4,959)(2,284)(69)49(7,263)Impact of bus

332、iness dispositions14261149Other comprehensive income(loss)beforereclassifications1,365(333)182(170)1,044(Income)loss amounts reclassified from accumulatedother comprehensive income(a)90(118)368Net current period other comprehensive income(loss)1,365(243)64(134)1,052Balance at December 31,2017$(3,452

333、)$(2,521)$(5)$(84)$(6,062)(a)Reclassified amounts for foreign currency translation adjustments are recorded in the Consolidated Statement of Earnings as Net Foreign exchange(gain)loss;gains(losses)on marketableequity securities are recorded as Other(income)expense and gains/losses related to cash flow hedges are recorded as Cost of product sold.Net actuarial losses and prior service cost isinclude